St Lukes Awarded Two HAP 2012 Achievement Awards
St. Luke's Awarded Two Hospital & Healthsystem Association of Pennsylvania (HAP) 2012 Achievement Awards
Both St. Luke's Hospital – Miners Campus and St. Luke's University Network Garner Recognition for Patient Safety Initiatives
Celebrating Recognition for
Patient Safety Initiatives
Bill Moyer, President, St. Luke's Hospital –
Miners Campus; Melissa Hartman, RPh,
Pharmacy Manager; Julie Kissinger,
Vice President for Communications &
Public Affairs, HAP; and radiologist
David Bohri, MD
Bethlehem, PA. (8/23/2012) – The Hospital & Healthsystem Association of Pennsylvania (HAP) recently recognized St. Luke's Hospital – Miners Campus with an award for the appropriate dosing of enoxaparin (Lovenox ®), a drug used to prevent formation of blood clots. The drug is used in patients who suffer from angina, heart attacks and who are at risk of developing blood clots in their legs.
St. Luke's Hospital – Miners Campus is the only hospital and St. Luke's University Health Network is the only network in the region selected as HAP winners this year.
Enoxaparin (Lovenox®) is a drug which is given to prevent the formation of blood clots. Patients who cannot clear the drug through their kidneys at normal rates may accumulate higher levels of the drug in their bodies, putting the patient at risk for side effects like excess bleeding and anemia.
In an average year, St. Luke's Hospital - Miners Campus typically administers more than 2,500 doses of enoxaparin to its patients. Baseline data from a three-month baseline period reflected that 77 percent of patients who were receiving enoxaparin received the appropriate dose based on their individual kidney function. An internal workgroup at the hospital set a goal of 100 percent to provide the highest quality of care to each patient.
By regularly obtaining and monitoring blood tests for creatinine output, the hospital pharmacists began to estimate the patient's kidney function and together with the physician insured each patient was receiving appropriate doses as approved by the Food and Drug Administration (FDA) and within the guidelines that the Miners Campus workgroup established. With the checks and balances systems in place, if discrepancies would occur at either the pharmacy or physician levels, the clinicians would discuss the blood results and adjust the individual dosage as necessary.
Nine months after beginning the project, 100 percent of patients receiving enoxaparin at St. Luke's Miners Campus were receiving appropriate doses for their kidney function. This result has been sustained for more than one year.
“Pennsylvania hospitals and health systems have been breaking new ground in quality and safety for decades. HAP congratulates you,” said Julie Kissinger, HAP Vice President of Communications & Public Affairs, to the Miners Campus team on August 23 when presenting the award. “Your story will serve as a guide and incentive to other health care providers.”
The following St. Luke's Hospital - Miners Campus team members and departments were recognized:
- Anthony Kanick, PharmD, Staff Pharmacist
- Lynn Mongi, RPh, Staff Pharmacist
- Melissa Hartman, PharmD, Pharmacy Manager
- Miners Department of Medicine
- Miners Department of Surgery
Additionally, HAP recognized St. Luke's University Health Network in June for reducing the rate at which women underwent elective deliveries of babies born at 39 weeks of gestation or earlier to 1.14 percent of all deliveries at the Bethlehem and Allentown Campuses. The national target rate is less than 5 percent.
The St. Luke's University Health Network and the hospitals within the network have won seven awards in the past three years.
Director, Network Media Relations